Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Hypertension Control in CKD Through Collaborative Pharmacist Interventions.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Correction to: Provision of Kidney Disease Education Service Is Associated with Improved Vascular Access Outcomes among US Incident Hemodialysis Patients.

Kidney360·2026
Same author

Association between estimated time with low glomerular filtration rate and access to transplant among youth with advanced chronic kidney disease.

Pediatric nephrology (Berlin, Germany)·2026
Same author

The impacts of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on rates of acute kidney injury in hospitalized adults receiving multiple nephrotoxins.

BMC nephrology·2026
Same author

Safety and Effectiveness of Spironolactone to Reduce Proteinuria in Kidney Transplant Recipients During a 5-Year Follow-Up.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation·2026
Same author

Bilateral Glomerulocystic Kidney Disease With Extensive Embryonal Hyperplasia in a Setting of <i>HNF1B</i> Mutation.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026

Related Experiment Video

Updated: Jun 13, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Uric acid and hypertension: cause or effect?

Marilda Mazzali1, Mehmet Kanbay, Mark S Segal

  • 1Division of Renal Diseases and Hypertension, University of Colorado-Denver, Aurora, CO 80045, USA.

Current Rheumatology Reports
|April 29, 2010
PubMed
Summary

High uric acid levels may contribute to high blood pressure. Early management of hyperuricemia could potentially delay the onset of essential hypertension, suggesting a causal role for uric acid.

More Related Videos

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

Related Experiment Videos

Last Updated: Jun 13, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • The association between uric acid and primary hypertension dates back to 1874.
  • Historically, elevated uric acid was considered a consequence of hypertension.
  • Emerging evidence suggests uric acid may play a role in the development of high blood pressure.

Purpose of the Study:

  • To review the current understanding of uric acid's role in primary hypertension.
  • To explore the potential mechanisms linking uric acid to elevated blood pressure.
  • To evaluate the implications of uric acid's involvement in hypertension pathogenesis.

Main Methods:

  • Review of historical and recent experimental and clinical studies.
  • Analysis of the potential pathogenic mechanisms of uric acid in hypertension.
  • Consideration of uric acid as a marker versus a causal factor.

Main Results:

  • While historically viewed as secondary, recent studies indicate uric acid may contribute to hypertension development.
  • Uric acid's precise role requires further investigation, including its link to xanthine oxidase-associated oxidants.
  • The collective evidence supports uric acid as a modifying and potentially causal factor in human primary hypertension.

Conclusions:

  • Uric acid is increasingly recognized as a potential contributor to the pathogenesis of primary hypertension.
  • Further research is needed to elucidate the specific mechanisms involved.
  • Managing hyperuricemia may be a strategy to prevent or delay essential hypertension.